系统性硬化症相关间质性肺病进展的预测因素
本文综述系统性硬化症相关间质性肺病(SSc-ILD)疾病进展的定义与预测方法。SSc-ILD是SSc患者主要死因,基线HRCT筛查有助确诊,但缺乏有效生物标志物预测发病与进展;作者建议以FVC下降≥10%或FVC下降5-9%伴DLCO下降≥15%定义进展,HRCT病变范围增加也提示进展,通常采用1-2年时间窗。
要点
- SSc-ILD是SSc患者首位死因,基线HRCT筛查是确诊必要手段。
- 建议FVC下降≥10%或FVC下降5-9%伴DLCO下降≥15%定义疾病进展。
- HRCT上ILD病变范围增加也提示疾病进展。
核心结论
- SSc-ILD尚无有效生物标志物预测发病,抗拓扑异构酶I抗体和部分炎症标志物为待评估的候选标志物。
- SSc-ILD疾病进展尚无统一有效定义,但可依据FVC和DLCO下降及HRCT病变范围增加判定。
- 患者临床病程个体差异大、难以预测,需监测疾病进展迹象,但监测工具与频率尚无共识。
研究设计与样本
- 本文为综述,汇总用于定义和预测SSc-ILD疾病进展的方法。
主要发现
- SSc-ILD是SSc患者的主要死因。
- 抗拓扑异构酶I自身抗体和若干炎症标志物为候选生物标志物,需进一步评估。
- 胸部听诊、气短和肺功能检查是重要诊断工具,但对早期ILD敏感性不足。
- 基线HRCT筛查是确认SSc-ILD诊断的必要手段。
- 部分患者特征和生物标志物与疾病进展相关。
关键数值与推荐
- FVC较基线下降≥10%,或FVC下降5-9%同时DLCO下降≥15%,代表疾病进展。
- HRCT影像上ILD范围增加也 signify 疾病进展。
- 该定义通常采用1-2年时间窗,但更长时间内的下降也可能反映临床相关的疾病进展。
临床怎么用
- 对SSc患者应行基线HRCT筛查以确认SSc-ILD诊断。
- 对确诊SSc-ILD患者应监测疾病进展迹象,可依据FVC、DLCO和HRCT变化判定。
局限性
- SSc-ILD疾病进展尚无有效定义。
- 缺乏有效生物标志物预测SSc-ILD的发生。
- 关于监测应使用何种诊断工具及监测频率尚无共识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic sclerosis (SSc) is a systemic autoimmune disease affecting multiple organ systems, including the lungs. Interstitial lung disease (ILD) is the leading cause of death in SSc.There are no valid biomarkers to predict the occurrence of SSc-ILD, although auto-antibodies against anti-topoisomerase I and several inflammatory markers are candidate biomarkers that need further evaluation. Chest auscultation, presence of shortness of breath and pulmonary function testing are important diagnostic tools, but lack sensitivity to detect early ILD. Baseline screening with high-resolution computed tomography (HRCT) is therefore necessary to confirm an SSc-ILD diagnosis. Once diagnosed with SSc-ILD, patients' clinical courses are variable and difficult to predict, although certain patient characteristics and biomarkers are associated with disease progression. It is important to monitor patients with SSc-ILD for signs of disease progression, although there is no consensus about which diagnostic tools to use or how often monitoring should occur. In this article, we review methods used to define and predict disease progression in SSc-ILD.There is no valid definition of SSc-ILD disease progression, but we suggest that either a decline in forced vital capacity (FVC) from baseline of ≥10%, or a decline in FVC of 5-9% in association with a decline in diffusing capacity of the lung for carbon monoxide of ≥15% represents progression. An increase in the radiographic extent of ILD on HRCT imaging would also signify progression. A time period of 1-2 years is generally used for this definition, but a decline over a longer time period may also reflect clinically relevant disease progression.
引用
- Distler O, Assassi S, Cottin V, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J. 2020. PMID: 32079645. doi:10.1183/13993003.02026-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。